Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology

Singh, Shivaram Prasad; Ahuja, Vineet; Ghoshal, Uday C; Makharia, Govind; Dutta, Usha; Zargar, Showkat Ali; Venkataraman, Jayanthi; Dutta, Amit Kumar; Mukhopadhyay, Asish K.; Singh, Ayaskanta; Thapa, Babu Ram; Vaiphei, Kim; Sathiyasekaran, Malathi; Sahu, Manoj Kumar; Rout, Niranjan; Abraham, Philip; Dalai, Prakash Chandra; Rathi, Pravin; Sinha, Saroj Kant; Bhatia, Shobna; Patra, Susama; Ghoshal, Ujjala; Poddar, Ujjal; Mouli, Venigalla Pratap; Kate, Vikram

doi:10.1007/s12664-021-01186-4

Cited by 16 publications

(18 citation statements)

References 206 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We read with interest the review article by Cho et al [ 1 ] where they have shown Helicobacter pylori ( H. pylori ) treatment guidelines in different countries. We would like to add views from India and the guidelines followed in India[ 2 ]. We hope this letter would be an insight into a better understanding of treatment regimens since the prevalence of H. pylori is very high (nearly 80%) in the indigent populations of many developing countries[ 3 ].…”

Section: To the Editormentioning

confidence: 99%

“…The American College of Gastroenterology also has similar recommendations[ 5 ]. Considering salvage therapies which include standard triple therapy that has not been previously used, bismuth-based quadruple therapy, levofloxacin-based therapy or rifabutin-based triple therapy[ 2 ]. In India, antibiotic susceptibility testing–based therapy is considered an option as third-line rescue therapy though not compulsory.…”

Section: To the Editormentioning

confidence: 99%

See 1 more Smart Citation

“Helicobacter pylori treatment guideline: An Indian perspective”: Letter to the editor

Swarnakar¹,

Yadav²

2022

World J Clin Cases

View full text Add to dashboard Cite

Treatment guidelines in many countries for Helicobacter pylori ( H. pylori ) may differ. Owing to the various characteristics of bacteria, clinical manifestations, resistance to antibiotics and recurrence rate, treatment regimens may change. In this letter, we would like to give an Indian perspective on H. pylori treatment guidelines.

show abstract

Section: To the Editormentioning

confidence: 99%

Section: To the Editormentioning

confidence: 99%

“Helicobacter pylori treatment guideline: An Indian perspective”: Letter to the editor

Swarnakar¹,

Yadav²

2022

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…In India, the eastern and southern parts of the country have a higher GC frequency than northern regions. Rice, non-vegetarian foods, mainly fish, are prevalent in the eastern Indian diet, which is spicy and with more salt [104]. In contrast, the northern Indian diet is wheat-based, and a greater proportion of people are vegetarian [104].…”

Section: Relationship Between Dietary Behavior Of the People And Risk Of Gcmentioning

confidence: 99%

“…Rice, non-vegetarian foods, mainly fish, are prevalent in the eastern Indian diet, which is spicy and with more salt [104]. In contrast, the northern Indian diet is wheat-based, and a greater proportion of people are vegetarian [104]. This observation suggests that geographical variations of dietary behavior are a significant component in the development and prevention of GC.…”

Section: Relationship Between Dietary Behavior Of the People And Risk Of Gcmentioning

confidence: 99%

Helicobacter pylori-Induced Inflammation: Possible Factors Modulating the Risk of Gastric Cancer

2021

Self Cite

View full text Add to dashboard Cite

Chronic inflammation and long-term tissue injury are related to many malignancies, including gastric cancer (GC). Helicobacter pylori (H. pylori), classified as a class I carcinogen, induces chronic superficial gastritis followed by gastric carcinogenesis. Despite a high prevalence of H. pylori infection, only about 1–3% of people infected with this bacterium develop GC worldwide. Furthermore, the development of chronic gastritis in some, but not all, H. pylori-infected subjects remains unexplained. These conflicting findings indicate that clinical outcomes of aggressive inflammation (atrophic gastritis) to gastric carcinogenesis are influenced by several other factors (in addition to H. pylori infection), such as gut microbiota, co-existence of intestinal helminths, dietary habits, and host genetic factors. This review has five goals: (1) to assess our current understanding of the process of H. pylori-triggered inflammation and gastric precursor lesions; (2) to present a hypothesis on risk modulation by the gut microbiota and infestation with intestinal helminths; (3) to identify the dietary behavior of the people at risk of GC; (4) to check the inflammation-related genetic polymorphisms and role of exosomes together with other factors as initiators of precancerous lesions and gastric carcinoma; and (5) finally, to conclude and suggest a new direction for future research.

show abstract

“…The relentless emergence and iteration of antimicrobial resistance (AMR) and its epidemiological spread dictates the continuous development of new antimicrobial agents and, perhaps more important, novel approaches to alter the trajectory of current resistance trends in key pathogens. − Current drug development efforts in this area are mainly focused on the identification of new modalities in existing approved antibiotic classes for the treatment of multidrug resistant Gram-positive and Gram-negative infections, such as methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Enterobacteriaceae (CRE), and carbapenem-resistant Acinetobacter baumannii (CRAB). Only limited efforts have been devoted to the development of new therapies for the treatment of anaerobic and microaerophilic bacterial infections, such as those caused by Helicobacter pylori , Clostridioides difficile and Gardnerella vaginosis , despite a growing unmet need in this area. − …”

Section: Introductionmentioning

confidence: 99%

Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens

Ma¹,

He²,

Yuan³

et al. 2022

J. Med. Chem.

View full text Add to dashboard Cite

TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitroimidazole pharmacophore, has been designed, synthesized, and evaluated as a novel dual-targeted antibacterial agent for the treatment of microaerophilic and anaerobic bacterial infections. TNP-2198 exhibits greater activity than a 1:1 molar mixture of the parent drugs and exhibits activity against strains resistant to both rifamycins and nitroimidazoles. A crystal structure of TNP-2198 bound to a Mycobacterium tuberculosis RNA polymerase transcription initiation complex reveals that the rifamycin portion of TNP-2198 binds to the rifamycin binding site on RNAP and the nitroimidazole portion of TNP-2198 interacts directly with the DNA template-strand in the RNAP active-center cleft, forming a hydrogen bond with a base of the DNA template strand. TNP-2198 is currently in Phase 2 clinical development for the treatment of Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis.

show abstract

Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology

Cited by 16 publications

References 206 publications

“Helicobacter pylori treatment guideline: An Indian perspective”: Letter to the editor

“Helicobacter pylori treatment guideline: An Indian perspective”: Letter to the editor

Helicobacter pylori-Induced Inflammation: Possible Factors Modulating the Risk of Gastric Cancer

Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens

Contact Info

Product

Resources

About